Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 9Pemetrexed 7Cyclophosphamide 6Nivolumab 5Ipilimumab 5Cisplatin 5Carboplatin 5fludarabine 4Drug Therapy 2Bevacizumab 2tremelimumab 1tocilizumab 1tazemetostat 1spartalizumab 1sotorasib 1rebastinib 1poly ICLC 1pevonedistat 1osimertinib 1milademetan 1fludarabine phosphate 1epacadostat 1durvalumab 1defactinib 1atezolizumab 1aldesleukin 1Vorinostat 1Thiostrepton 1Tablets 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma × rebastinib × Clear all
NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡